With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it.
As ETR occurs, Xeltis implants are gradually absorbed by the body.
ETR is enabled by the porous structure of Xeltis’ devices, which are made of bioabsorbable polymers, based on Nobel-prize awarded science.
Key Benefits
01
Xeltis’ restorative devices may help overcome the limitations of current artificial blood vessels or heart valves.
02
Xeltis cardiovascular devices may help reduce the need for repeated replacement procedures, invasive vessel harvesting and long-term medication with their potentially severe side effects.
03
Xeltis devices may help improve quality of life for patients who need blood vessel and heart valve replacement.
04
Xeltis cardiovascular therapy may help reduce the overall cost of blood vessel and heart valve disease treatment.
Milestones
Over 25 pediatric patients have been implanted with Xeltis’ cardiovascular devices in ongoing trials;
The first few patients have now completed their five-year follow-up.
Xeltis’ aortic valve and small diameter cardiovascular grafts are in preclinical trials.
Long-term preclinical trial results of Xeltis’ heart valve and vascular applications support the promise to naturally restore cardiovascular function.
